The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $255.44

Today's change+2.98 +1.18%
Updated July 31 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $255.44

Today's change+2.98 +1.18%
Updated July 31 4:00 PM -4GMT. Delayed by at least 15 minutes.

Spdr S&P Biotech Etf up (U.S.)$2.98

Spdr S&P Biotech Etf closed up Friday by (U.S.)$2.98 or 1.18% to (U.S.)$255.44. Over the last five days, shares are unchanged, but have gained 36.99% over the last year to date. This security has outperformed the S&P 500 by 65.75% during the last year.

Key company metrics

  • Open(U.S.) $252.92
  • Previous close(U.S.) $252.46
  • High(U.S.) $258.82
  • Low(U.S.) $251.30
  • Bid / Ask(U.S.) $254.81 / (U.S.) $256.02
  • YTD % change+36.99%
  • Volume962,924
  • Average volume (10-day)1,256,582
  • Average volume (1-month)1,240,052
  • Average volume (3-month)1,145,457
  • 52-week range(U.S.) $141.85 to (U.S.) $273.33
  • Beta1.06
  • Trailing P/E4.67×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $1.74
  • Dividend yield0.68%
  • Trailing EPS(U.S.) $54.69
Updated July 31 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2,202.84%

Based on its net profit margin of 2,202.84%, Spdr S&P Biotech Etf is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.60%Sector:FinancialsIndustry:Investment Trusts
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q4/2014Q2/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Jun 30, 201406/30/2014Dec 31, 201312/31/2013Jun 30, 201306/30/2013
Revenue81032
Total other revenue--------
Total revenue81032
Gross profit--------
Total cost of revenue--------
Total operating expense2221
Selling / general / administrative2221
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income6811
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax262141200125
Income after tax262141200125
Income tax, total--000
Net income262141200125
Total adjustments to net income--------
Net income before extra. items262141200125
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items262141200125
Inc. avail. to common incl. extra. items262141200125
Diluted net income262141200125
Dilution adjustment--------
Diluted weighted average shares8789
Diluted EPS excluding extraordinary itemsvalue per share33.6221.0726.0113.83
Dividends per sharevalue per share1.050.940.130.09
Diluted normalized EPSvalue per share33.6221.0726.0113.83